Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

        The table above is based on 232,421,677 shares outstanding as of June 30, 2014 after giving effect to the automatic preferred stock conversion and excludes:

    1,045,834 shares issuable upon the exercise of warrants outstanding as of June 30, 2014, at a weighted-average exercise price of $1.19 per share;
    35,252,515 shares of common stock issuable upon the exercise of options outstanding as of June 30, 2014, with a weighted-average exercise price of $0.19 per share;
    9,000,000 shares of common stock subject to RSUs outstanding as of June 30, 2014;
    1,070,687 shares of common stock reserved for future grants under our 2013 Stock Plan, 2004 Stock Plan and 2001 Stock Plan as of June 30, 2014;
    shares of common stock reserved for future grants under our 2014 Equity Incentive Plan, which became effective in                    2014 (subject to automatic annual adjustment in accordance with the terms of the plan), but with respect to which no awards will be granted prior to the completion of the offering; and
    shares reserved for future issuance under our 2014 Employee Stock Purchase Plan, which became effective in                     2014 but with respect to which no shares will be purchased prior to the effective date of the registration statement of which this prospectus is a part, subject to automatic annual adjustment in accordance with the terms of the plan.

        To the extent that any outstanding options or warrants are exercised or new options are issued under our incentive plans, there will be further dilution to investors participating in this offering.

51